Symbols / DTIL
DTIL Chart
About
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 96.29M |
| Enterprise Value | 37.29M | Income | -83.60M | Sales | 698.00K |
| Book/sh | 1.38 | Cash/sh | 3.38 | Dividend Yield | — |
| Payout | 0.00% | Employees | 67 | IPO | — |
| P/E | — | Forward P/E | -1.29 | PEG | — |
| P/S | 137.95 | P/B | 2.90 | P/C | — |
| EV/EBITDA | -0.42 | EV/Sales | 53.42 | Quick Ratio | 2.99 |
| Current Ratio | 3.45 | Debt/Eq | 175.11 | LT Debt/Eq | — |
| EPS (ttm) | -8.96 | EPS next Y | -3.11 | EPS Growth | — |
| Revenue Growth | -97.70% | Earnings | 2026-03-31 | ROA | -45.34% |
| ROE | -205.16% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -1589.77% | Profit Margin | 0.00% | Shs Outstand | 24.07M |
| Shs Float | 10.17M | Short Float | 5.81% | Short Ratio | 5.67 |
| Short Interest | — | 52W High | 8.82 | 52W Low | 3.53 |
| Beta | 1.31 | Avg Volume | 218.70K | Volume | 93.48K |
| Target Price | $32.50 | Recom | None | Prev Close | $3.95 |
| Price | $4.00 | Change | 1.27% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$32.50
Mean price target
2. Current target
$4.00
Latest analyst target
3. DCF / Fair value
$-27.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.00
Low
$19.00
High
$60.00
Mean
$32.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-01-10 | up | BMO Capital | Market Perform → Outperform | $34 |
| 2024-05-30 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2024-04-30 | init | Guggenheim | — → Buy | $19 |
| 2024-04-17 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2024-03-28 | main | HC Wainwright & Co. | Buy → Buy | $60 |
| 2024-02-14 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
- Scimeca, Precision Bio general counsel, sells $35,681 in DTIL stock - Investing.com hu, 22 Jan 2026 08
- Precision Biosciences: Still Swinging And Finally Drawing Blood (NASDAQ:DTIL) - Seeking Alpha hu, 04 Dec 2025 08
- Gene editing effort targets new options for hepatitis B and Duchenne - Stock Titan Mon, 12 Jan 2026 08
- Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last? - Yahoo Finance hu, 16 Oct 2025 07
- Insider Purchase: Director at $DTIL Buys 3,000 Shares | DTIL Stock News - Quiver Quantitative Wed, 17 Dec 2025 08
- Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy - Business Wire Wed, 11 Feb 2026 08
- A great week that adds to Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns, institutional investors who own 46% must be happy - simplywall.st Fri, 31 Oct 2025 07
- Precision BioSciences Inc (NASDAQ:DTIL) Stock Falls After Q3 2025 Earnings and Revenue Miss - ChartMill Mon, 03 Nov 2025 08
- DTIL Stock: Surge or Bubble? - StocksToTrade Wed, 25 Jun 2025 07
- $DTIL stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Mon, 03 Nov 2025 08
- Insider Buying: Stanley Frankel Acquires Additional Shares of Pr - GuruFocus Wed, 17 Dec 2025 08
- Why DTIL stock could rally in 2025 - 2025 Sector Review & Free Risk Controlled Daily Trade Plans - mfd.ru Wed, 18 Feb 2026 14
- Biotech recruits new hire with 8,224 stock units vesting over 3 years - Stock Titan ue, 23 Dec 2025 08
- Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants - Business Wire Mon, 10 Nov 2025 08
- Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL) - Seeking Alpha Mon, 29 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4925 | 18912.0 | — | Sale at price 3.84 per share. | SMITH J JEFFERSON | Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 4925 | 18912.0 | — | Sale at price 3.84 per share. | SCIMECA DARIO JOSEPH | General Counsel | — | 2026-02-18 00:00:00 | D |
| 2 | 20559 | 78947.0 | — | Sale at price 3.84 per share. | AMOROSO MICHAEL | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 8149 | 31292.0 | — | Sale at price 3.84 per share. | KELLY JOHN ALEXANDER | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 4 | 16667 | nan | — | — | SMITH J JEFFERSON | Officer | — | 2026-02-17 00:00:00 | D |
| 5 | 16667 | nan | — | — | SCIMECA DARIO JOSEPH | General Counsel | — | 2026-02-17 00:00:00 | D |
| 6 | 67797 | nan | — | — | AMOROSO MICHAEL | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 7 | 27584 | nan | — | — | KELLY JOHN ALEXANDER | Chief Financial Officer | — | 2026-02-17 00:00:00 | D |
| 8 | 34799 | 145112.0 | — | Sale at price 4.17 per share. | AMOROSO MICHAEL | Chief Executive Officer | — | 2026-01-22 00:00:00 | D |
| 9 | 10200 | 41106.0 | — | Sale at price 4.03 per share. | SMITH J JEFFERSON | Officer | — | 2026-01-21 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.65M | -31.58M | -51.41M | -28.79M |
| TotalUnusualItems | 29.17M | -461.00K | -11.38M | 8.51M |
| TotalUnusualItemsExcludingGoodwill | 29.17M | -461.00K | -11.38M | 8.51M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 7.17M | -42.53M | -72.91M | -30.60M |
| ReconciledDepreciation | 4.58M | 8.26M | 9.00M | 10.20M |
| EBITDA | 13.53M | -32.04M | -62.79M | -20.27M |
| EBIT | 8.95M | -40.30M | -71.80M | -30.47M |
| NetInterestIncome | 4.98M | 5.46M | 2.36M | 76.00K |
| InterestExpense | 1.78M | 2.23M | 1.11M | 132.00K |
| InterestIncome | 6.76M | 7.69M | 3.47M | 208.00K |
| NormalizedIncome | -22.01M | -42.07M | -61.52M | -39.12M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 7.17M | -61.32M | -111.64M | -30.60M |
| TotalExpenses | 94.86M | 92.46M | 87.41M | 154.91M |
| TotalOperatingIncomeAsReported | -26.16M | -43.74M | -62.31M | -39.38M |
| DilutedAverageShares | 6.88M | 3.84M | 2.93M | 1.96M |
| BasicAverageShares | 6.83M | 3.84M | 2.93M | 1.96M |
| DilutedEPS | 1.04 | -15.96 | -38.10 | -15.60 |
| BasicEPS | 1.05 | -15.96 | -38.10 | -15.60 |
| DilutedNIAvailtoComStockholders | 7.17M | -61.32M | -111.64M | -30.60M |
| NetIncomeCommonStockholders | 7.17M | -61.32M | -111.64M | -30.60M |
| NetIncome | 7.17M | -61.32M | -111.64M | -30.60M |
| NetIncomeIncludingNoncontrollingInterests | 7.17M | -61.32M | -111.64M | -30.60M |
| NetIncomeDiscontinuousOperations | 0.00 | -18.79M | -38.73M | |
| NetIncomeContinuousOperations | 7.17M | -42.53M | -72.91M | -30.60M |
| PretaxIncome | 7.17M | -42.53M | -72.91M | -30.60M |
| OtherIncomeExpense | 28.35M | -4.25M | -12.96M | 8.70M |
| OtherNonOperatingIncomeExpenses | 258.00K | 1.15M | ||
| SpecialIncomeCharges | -436.00K | -461.00K | -10.87M | 5.96M |
| GainOnSaleOfPPE | -436.00K | -461.00K | -30.00K | -26.00K |
| GainOnSaleOfBusiness | 0.00 | 5.99M | ||
| WriteOff | 0.00 | 10.84M | 0.00 | |
| EarningsFromEquityInterest | -1.08M | -4.93M | -1.58M | 184.00K |
| GainOnSaleOfSecurity | 29.61M | 1.15M | -510.00K | 2.56M |
| NetNonOperatingInterestIncomeExpense | 4.98M | 5.46M | 2.36M | 76.00K |
| InterestExpenseNonOperating | 1.78M | 2.23M | 1.11M | 132.00K |
| InterestIncomeNonOperating | 6.76M | 7.69M | 3.47M | 208.00K |
| OperatingIncome | -26.16M | -43.74M | -62.31M | -39.38M |
| OperatingExpense | 94.86M | 92.46M | 87.41M | 154.91M |
| ResearchAndDevelopment | 59.56M | 53.38M | 46.12M | 115.24M |
| SellingGeneralAndAdministration | 35.30M | 39.09M | 41.28M | 39.67M |
| GeneralAndAdministrativeExpense | 35.30M | 39.09M | 41.28M | 39.67M |
| OtherGandA | 35.30M | 39.09M | 41.28M | 39.67M |
| TotalRevenue | 68.70M | 48.73M | 25.10M | 115.53M |
| OperatingRevenue | 68.70M | 48.73M | 25.10M | 115.53M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 27.02K | 27.01K | 27.02K | 27.02K |
| OrdinarySharesNumber | 8.20M | 4.16M | 3.70M | 2.03M |
| ShareIssued | 8.23M | 4.19M | 3.73M | 2.06M |
| TotalDebt | 30.05M | 31.27M | 24.96M | 9.11M |
| TangibleBookValue | 55.77M | 18.46M | 59.70M | 89.12M |
| InvestedCapital | 78.71M | 41.27M | 82.66M | 93.65M |
| WorkingCapital | 80.01M | 86.37M | 139.44M | 125.77M |
| NetTangibleAssets | 55.77M | 18.46M | 59.70M | 89.12M |
| CapitalLeaseObligations | 7.72M | 8.86M | 2.74M | 6.63M |
| CommonStockEquity | 56.39M | 18.86M | 60.43M | 91.17M |
| TotalCapitalization | 78.71M | 18.86M | 82.66M | 93.65M |
| TotalEquityGrossMinorityInterest | 56.39M | 18.86M | 60.43M | 91.17M |
| StockholdersEquity | 56.39M | 18.86M | 60.43M | 91.17M |
| TreasuryStock | 952.00K | 952.00K | 952.00K | 952.00K |
| RetainedEarnings | -482.46M | -489.63M | -428.31M | -316.68M |
| AdditionalPaidInCapital | 539.81M | 509.44M | 489.70M | 408.80M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 0.00 |
| CommonStock | 1.00K | 1.00K | 1.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 80.00M | 140.92M | 177.74M | 120.33M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 65.02M | 90.93M | 118.07M | 84.35M |
| OtherNonCurrentLiabilities | 194.00K | 128.00K | 201.00K | 44.00K |
| LiabilitiesHeldforSaleNonCurrent | 128.00K | 1.72M | ||
| DerivativeProductLiabilities | 2.80M | 0.00 | ||
| NonCurrentDeferredLiabilities | 33.30M | 83.08M | 92.87M | 77.02M |
| NonCurrentDeferredRevenue | 33.30M | 83.08M | 92.87M | 77.02M |
| LongTermDebtAndCapitalLeaseObligation | 28.73M | 7.72M | 23.28M | 7.29M |
| LongTermCapitalLeaseObligation | 6.40M | 7.72M | 1.06M | 4.81M |
| LongTermDebt | 22.32M | 22.22M | 2.48M | |
| CurrentLiabilities | 14.98M | 49.99M | 59.66M | 35.98M |
| OtherCurrentLiabilities | 2.19M | 4.90M | 4.21M | 977.00K |
| CurrentDeferredLiabilities | 2.96M | 12.04M | 46.19M | 21.24M |
| CurrentDeferredRevenue | 2.96M | 12.04M | 46.19M | 21.24M |
| CurrentDebtAndCapitalLeaseObligation | 1.32M | 23.55M | 1.68M | 1.82M |
| CurrentCapitalLeaseObligation | 1.32M | 1.13M | 1.68M | 1.82M |
| CurrentDebt | 22.41M | |||
| OtherCurrentBorrowings | 22.41M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.18M | 4.98M | 5.10M | 6.76M |
| PayablesAndAccruedExpenses | 3.33M | 4.53M | 2.48M | 5.17M |
| CurrentAccruedExpenses | 2.02M | 1.56M | 1.83M | 4.03M |
| Payables | 1.31M | 2.97M | 653.00K | 1.14M |
| AccountsPayable | 1.31M | 2.97M | 653.00K | 1.14M |
| TotalAssets | 136.39M | 159.78M | 238.17M | 211.50M |
| TotalNonCurrentAssets | 41.40M | 23.42M | 39.06M | 49.74M |
| OtherNonCurrentAssets | 22.79M | 225.00K | 12.57M | 4.64M |
| NonCurrentNoteReceivables | 4.60M | 4.99M | 7.23M | 6.88M |
| InvestmentsAndAdvances | 3.21M | 3.21M | 4.75M | 6.84M |
| InvestmentinFinancialAssets | 3.21M | 3.21M | 2.58M | 3.09M |
| AvailableForSaleSecurities | 3.21M | 3.21M | 2.58M | 3.09M |
| LongTermEquityInvestment | 0.00 | 2.17M | 3.75M | |
| InvestmentsInOtherVenturesUnderEquityMethod | 3.75M | |||
| GoodwillAndOtherIntangibleAssets | 622.00K | 400.00K | 731.00K | 2.05M |
| OtherIntangibleAssets | 622.00K | 400.00K | 731.00K | 2.05M |
| NetPPE | 10.18M | 14.60M | 13.78M | 29.33M |
| AccumulatedDepreciation | -28.08M | -25.49M | -21.87M | -23.91M |
| GrossPPE | 38.26M | 40.09M | 35.65M | 53.25M |
| Leases | 12.03M | 11.95M | 11.95M | 22.78M |
| ConstructionInProgress | 9.00K | 70.00K | 520.00K | 3.04M |
| OtherProperties | 22.18M | 24.12M | 19.23M | 23.47M |
| MachineryFurnitureEquipment | 4.04M | 3.96M | 3.95M | 3.95M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 94.99M | 136.36M | 199.10M | 161.75M |
| OtherCurrentAssets | 369.00K | 419.00K | 1.23M | 169.00K |
| AssetsHeldForSaleCurrent | 169.00K | 487.00K | 1.56M | |
| PrepaidAssets | 6.44M | 5.98M | 6.03M | 17.43M |
| Receivables | 1.70M | 12.80M | 720.00K | 488.00K |
| OtherReceivables | 1.47M | |||
| NotesReceivable | 0.00 | 11.90M | 0.00 | |
| AccountsReceivable | 229.00K | 901.00K | 720.00K | 488.00K |
| CashCashEquivalentsAndShortTermInvestments | 86.31M | 116.68M | 189.58M | 143.66M |
| OtherShortTermInvestments | 413.00K | 0.00 | ||
| CashAndCashEquivalents | 85.90M | 116.68M | 189.58M | 143.66M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -58.72M | -86.39M | -49.07M | -16.66M |
| RepaymentOfDebt | -22.50M | 0.00 | 0.00 | -2.50M |
| IssuanceOfDebt | 22.47M | 0.00 | 19.80M | 4.97M |
| IssuanceOfCapitalStock | 50.24M | 4.99M | 74.34M | 60.48M |
| CapitalExpenditure | -275.00K | -2.28M | -3.32M | -5.80M |
| InterestPaidSupplementalData | 1.74M | 2.02M | 824.00K | 68.00K |
| EndCashPosition | 108.47M | 116.68M | 189.58M | 143.66M |
| BeginningCashPosition | 116.68M | 189.58M | 143.66M | 89.80M |
| ChangesInCash | -8.21M | -72.90M | 45.91M | 53.87M |
| FinancingCashFlow | 50.45M | 5.39M | 94.98M | 70.52M |
| CashFlowFromContinuingFinancingActivities | 50.45M | 5.39M | 94.98M | 70.52M |
| NetOtherFinancingCharges | -13.00K | |||
| ProceedsFromStockOptionExercised | 249.00K | 401.00K | 835.00K | 7.59M |
| NetCommonStockIssuance | 50.24M | 4.99M | 74.34M | 60.48M |
| CommonStockIssuance | 50.24M | 4.99M | 74.34M | 60.48M |
| NetIssuancePaymentsOfDebt | -37.00K | 0.00 | 19.80M | 2.47M |
| NetShortTermDebtIssuance | 0.00 | 19.80M | 2.50M | |
| ShortTermDebtIssuance | 0.00 | 19.80M | 2.50M | |
| NetLongTermDebtIssuance | -37.00K | 0.00 | 0.00 | -35.00K |
| LongTermDebtPayments | -22.50M | 0.00 | 0.00 | -2.50M |
| LongTermDebtIssuance | 22.47M | 0.00 | 0.00 | 2.46M |
| InvestingCashFlow | -215.00K | 5.83M | -3.32M | -5.80M |
| CashFlowFromContinuingInvestingActivities | -215.00K | 5.83M | -3.32M | -5.80M |
| NetBusinessPurchaseAndSale | 0.00 | 8.00M | 0.00 | |
| SaleOfBusiness | 0.00 | 8.00M | 0.00 | |
| NetIntangiblesPurchaseAndSale | -25.00K | -321.00K | 0.00 | -750.00K |
| PurchaseOfIntangibles | -25.00K | -321.00K | 0.00 | -750.00K |
| NetPPEPurchaseAndSale | -190.00K | -1.85M | -3.32M | -5.05M |
| SaleOfPPE | 60.00K | 107.00K | 0.00 | |
| PurchaseOfPPE | -250.00K | -1.96M | -3.32M | -5.05M |
| OperatingCashFlow | -58.45M | -84.11M | -45.75M | -10.85M |
| CashFlowFromContinuingOperatingActivities | -58.45M | -84.11M | -45.75M | -10.85M |
| ChangeInWorkingCapital | -54.00M | -41.49M | 24.11M | 19.58M |
| ChangeInOtherWorkingCapital | -56.87M | -43.95M | 27.36M | 6.84M |
| ChangeInOtherCurrentLiabilities | -3.26M | -1.67M | -3.64M | -513.00K |
| ChangeInOtherCurrentAssets | -262.00K | 1.75M | 1.43M | -2.73M |
| ChangeInPayablesAndAccruedExpense | -2.10M | 1.51M | 153.00K | 867.00K |
| ChangeInPayable | -2.10M | 1.51M | 153.00K | 867.00K |
| ChangeInAccountPayable | -2.10M | 1.51M | 153.00K | 867.00K |
| ChangeInPrepaidAssets | -464.00K | 1.05M | -962.00K | 5.62M |
| ChangeInReceivables | 8.95M | -181.00K | -232.00K | 9.51M |
| ChangesInAccountReceivables | 672.00K | -181.00K | -232.00K | 9.51M |
| OtherNonCashItems | -446.00K | -147.00K | 450.00K | -20.40M |
| StockBasedCompensation | 12.60M | 14.04M | 19.20M | 16.51M |
| UnrealizedGainLossOnInvestmentSecurities | -258.00K | -1.15M | ||
| AssetImpairmentCharge | 0.00 | 641.00K | 11.44M | 0.00 |
| DepreciationAmortizationDepletion | 4.58M | 8.26M | 9.00M | 10.20M |
| DepreciationAndAmortization | 4.58M | 8.26M | 9.00M | 10.20M |
| Depreciation | 4.58M | 8.26M | 9.00M | 10.20M |
| OperatingGainsLosses | -28.09M | -2.95M | 1.69M | -6.14M |
| EarningsLossesFromEquityInvestments | 1.08M | 4.93M | 1.58M | -184.00K |
| GainLossOnInvestmentSecurities | -29.61M | |||
| GainLossOnSaleOfBusiness | 0.00 | -8.45M | 0.00 | -5.99M |
| NetIncomeFromContinuingOperations | 7.17M | -61.32M | -111.64M | -30.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DTIL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|